解氏肺癌三号方在非小细胞肺癌患者放化疗治疗中的应用及对血清肿瘤标记物、放疗毒副反应的影响

Application of XIE’s Lung Cancer No.3Prescription in Chemoradiotherapy for NSCLC Patients and Its Influ-ences on Serum Tumor Markers and Radiotherapy Side Effects

目的:探讨解氏肺癌三号方在非小细胞肺癌(NSCLC)患者放化疗治疗中的应用及对血清肿瘤标记物、放疗毒副反应的影响。方法:选取2018年1月~2018年12月本院收治的96例NSCLC患者,以随机数值表法分为观察组、对照组各48例。对照组给予放疗+化疗(吉西他滨+顺铂)方案;观察组在对照组的基础上给予解氏肺癌3号方治疗。于治疗结束后1月评估临床有效率(RR)及疾病控制率(DCR);检测两组治疗前后癌胚抗原(CEA)、糖类抗原12-5(CA12-5)、细胞角蛋白19片段21-1(CYFRA21-1)含量;采用卡氏评分评估患者生存质量情况;记录放疗毒副反应发生情况。结果:观察组患者的DCR、总有效率(83.33%;91.67%)均显著高于对照组(64.58%;75.00%)(χ^2=4.381,P=0.036;χ^2=4.800,P=0.028)。治疗后,两组患者的CEA、CA12-5及CYFRA21-1均较治疗前明显下降(P<0.05);且观察组治疗后的CEA、CA12-5及CYFRA21-1较对照组治疗后下降得更为显著(t=9.031,P=0.000;t=18.338,P=0.000;t=12.706,P=0.000)。观察组患者的放射性肺炎、放射性食管炎发生率均显著低于对照组(χ^2=4.381,P=0.036;χ^2=3.859,P=0.049)结论:解氏肺癌三号方能有效降低NSCLC患者血清CEA、CA12-5及CYFRA21-1水平、减少放疗毒副反应的发生,提升患者生存质量。

Objective:To explore the application of XIE’s Lung Cancer No.3Prescription in chemoradiotherapy for pa-tients with non-small cell lung cancer(NSCLC)and its influences on serum tumor markers and radiotherapy side effects.Meth-ods:96NSCLC patients who were admitted to the hospital from January 2018to December 2018were enrolled.They were divided into observation group and controlled group by random number table method,48cases in each group.The controlled group was given radiotherapy and chemotherapy(gemcitabine and cisplatin)program.On the basis of the controlled group,the observation group was given XIE’s Lung Cancer No.3Prescription.At 1month after end of treatment,clinical response rate(RR)and dis-ease control rate(DCR)were evaluated.The contents of carcinoembryonic antigen(CEA),carbohydrate antigen 12~5(CA12~5)and cytokeratin 19fragments 21~1(CYFRA21~1)in both groups before and after treatment were detected.The quality of life was assessed by Kamofsky Performance Status.The occurrence of radiotherapy side effects was recorded.Results:DCR and total response rate in the observation group were significantly higher than those in the controlled group(83.33%,91.67%vs 64.58%,75.00%)(χ^2=4.381,P=0.036;χ^2=4.800,P=0.028).After treatment,CEA,CA12~5and CYFRA21~1in both groups were significantly decreased(P<0.05).And decrease of the above indexes in the observation group was more signifi-cant than that in the controlled group(t=9.031,P=0.000;t=18.338,P=0.000;t=12.706,P=0.000).The incidence of radiation pneumonitis and radiation esophagitis in the observation group was significantly lower than that in the controlled group(χ^2=4.381,P=0.036;χ^2=3.859,P=0.049).Conclusion:XIE’s Lung Cancer No.3Prescription can effectively reduce levels of serum CEA,CA12~5and CYFRA21~1in NSCLC patients,reduce occurrence of radiotherapy side effects,and im-prove their quality of life.